Poxel S.A.
Poxel Announces Data Presentations at American Diabetes Association (ADA) Annual Meeting in San Francisco
Poxel S.A. / Key word(s): Miscellaneous
Poxel Announces Data Presentations at American Diabetes Association (ADA) Annual Meeting in San Francisco
– Selected by ADA for oral communications and poster presentation – Presentation of preclinical and clinical mechanistic data on IMEGLIMIN, 1st in a new class of oral anti-diabetic agents, the Glimins LYON, France, June 6, 2014 – Poxel SA will present new Phase 2 data from human and animal studies with its novel anti-diabetic agent – IMEGLIMIN – currently in Phase 2b clinical development, during the 74th Scientific Session of the American Diabetes Association being held at the Moscone Center in San Francisco from June 13 to June 17, 2014. The data to be presented demonstrate Imeglimin’s dual activity on both insulin sensitizing and insulin secretion defects of Type 2 Diabetes, featuring the innovative profile of this new anti-diabetic agent. The presentations are: Oral communication: “Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity in Improving Mitochondrial Function in a High-Fat-High Sucrose Diet Mice Model” will be presented by Sophie Hallakou-Bozec, PhD (Poxel SA) on Saturday, June 14, 2014, Room: S-307 (South Building) at 1:45 pm PT, # 119-OR in category “Novel Therapeutics Agents”. Oral communication: “Imeglimin Increases Glucose-Dependent Insulin Secretion and Improves Beta-cell Function in Patients with Type 2 Diabetes” will be presented by Michael Roden, MD (Institute for Clinical Diabetology, German Diabetes Center, Department of Endocrinology and Diabetology, University Hospital Düsseldorf, Düsseldorf, Germany) on Saturday, June 14, 2014, Room: S-307 (South Building) at 2:00 pm PT, # 120-OR in category “Novel Therapeutics Agents”. Poster presentation: “Imeglimin Decreases Hepatic Glucose Production through a Unique Mitochondrial Mechanism of Action” will be presented by Guillaume Vial PhD (INSERM U1060, Faculté de Médecine Lyon Sud; European Center for Nutrition and Health, Centre Hospitalier Lyon Sud) on Sunday 15 June, 2014, noon – 2:00 pm PT, # 1067-P in category 01-E Clinical Therapeutics/New Technology – Oral Agents. Poxel’s chief medical officer Dr. Pascale Fouqueray stated: “We will present human and animal data that demonstrates the uniqueness of Imeglimin, as it improves glucose-stimulated insulin secretion, normalizes glucose tolerance and improves insulin sensitivity through a mitochondrial-based mechanism. With this unique mechanism of action, Imeglimin could represent a new way of addressing the pathophysiology underlying Type 2 Diabetes“. The presentation abstracts can be accessed by registered meeting attendees through the association’s web site, www.diabetes.org. About Imeglimin Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas and has therefore a distinct mode of action compared to existing treatments for Type 2 Diabetes. In that, it looks like the best partner to complement other treatments. Imeglimin phase 2a monotherapy results were published in Diabetes, Obesity and Metabolism in April 2012. In October 2011, Poxel reported phase 2 results of Imeglimin as add-on therapy to metformin in patients inadequately controlled with metformin monotherapy. This study achieved its primary end-point of superiority in HbA1c reduction versus placebo (p<0.001). The study results are published in Diabetes Care. In November 2012, Poxel reported phase 2 results of Imeglimin as add-on therapy to sitagliptin in patients inadequately controlled with sitagliptin monotherapy. This study achieved its primary end-point of superiority in HbA1c reduction versus placebo (p<0.001). The study results are published in Diabetes Care. About Poxel SA Poxel, founded in 2009, is a biopharmaceutical company developing innovative first-in-class drugs, with a primary focus on Type 2 Diabetes. The company develops novel treatments before seeking pharmaceutical industry partners. Poxel was spun out from Merck Serono and now operates independently as a lean organization with strong in-house drug development and business expertise. Poxel’s product pipeline consists of several first-in-class Type 2 Diabetes candidates, including Imeglimin in phase 2b clinical development and a direct activator of AMPK, close to phase1 development for the treatment of Type 2 Diabetes. For more information, please visit www.poxel.com Media Contacts Poxel SA End of Corporate News 06.06.2014 Dissemination of a Corporate News, transmitted by DGAP – a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
272593 06.06.2014 |